If we only treat high - risk
individuals with aspirin, we are going to miss a substantial portion of patients who eventually suffer heart attacks.
Not exact matches
Previous genetic studies have examined the association of
aspirin, NSAIDs, or both
with colorectal cancer according to a limited number of candidate genes or pathways.6 - 10 Thus, to comprehensively identify common genetic markers that characterize
individuals who may obtain differential benefit from
aspirin and NSAIDs, we conducted a discovery - based, genome - wide analysis of gene × environment interactions between regular use of
aspirin, NSAIDs, or both and single - nucleotide polymorphisms (SNPs) in relation to risk of colorectal cancer.
«We estimate that
individuals with significant plaque buildup in the arteries of the heart are much more likely to prevent a heart attack
with aspirin use than to suffer a significant bleed» explains Miedema.
«
Individuals with known CVD [cardiovascular disease] should take a daily aspirin, but the best approach for individuals without known CVD
Individuals with known CVD [cardiovascular disease] should take a daily
aspirin, but the best approach for
individuals without known CVD
individuals without known CVD is unclear.
The findings should push more people toward the AHA and USPSTF advice, which calls for people to discuss
with their doctor their
individual risk and benefit ratio, rather than deciding that
aspirin is or isn't right for them based on the drug's label.
In adults ages 60 to 69 years, who have a calculated heart risk over the next 10 years greater than 10 %, the decision to use a daily low - dose
aspirin is an
individual one
with the same comments as in number two above.
Just like in people
with the various non-steroidal products like ibuprofen,
aspirin and acetaminophen, one sometimes works better for a particular
individual than the other one.
Individuals below 19 years of age
with a rare and fatal disease of Reye's syndrome, and receiving «long - term»
aspirin therapy